Ask AI
ProCE Banner Activity

A Changing Treatment Paradigm of Myasthenia Gravis: A Focus on Novel Targeted Treatments

Slideset

This presentation will educate healthcare providers on the historical treatment of myasthenia gravis, how the newer agents change the treatment paradigm, and demonstrate how to treat various subtypes of myasthenia gravis through patient case examples.

Released: September 23, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Jonathan Katz, MD

Director
Department of Neurology
Forbes Norris MDA ALS Center
California Pacific Medical Center
San Francisco, California

Jonathan Katz, MD: consultant/advisor/speaker: Alexion, Argenx, Biogen, Calico, Denali, Grifols, PTC Therapeutics, Takeda, Wave Life Sciences.

Gil I. Wolfe, MD, FAAN

SUNY Distinguished Professor
Neuromuscular Division
Department of Neurology 
University of Buffalo Jacobs School of Medicine and Biomedical Sciences
State University of New York
Buffalo, New York

Gil Wolfe, MD, FAAN: consultant/advisor/speaker: Alexion, Argenx, Grifols, Janssen, Takeda, UCB; researcher: Roche, Sanofi.